Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services | News
Search Refinements

Contract Services News

View news from other Pharmaceutical sectors:
121-135 of 2369 results
Akari Therapeutics, XL-protein sign license deal to develop long acting version of Coversin
Akari Therapeutics and XL-protein, a privately owned biopharmaceutical company, announced today that they have entered into a License, Development and Commercialization Agreement.
Contract Research & Services > Contract Services > News
Aires Pharmaceuticals inks deal with Duke University for Phase 2 study of AIR001 in HFpEF patients
Mast Therapeutics' subsidiary, Aires Pharmaceuticals, has entered into an agreement with Duke University to provide support for a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study of the Company's product candidate AIR001 in patients with heart failure with preserved ejection fraction (HFpEF).
Contract Research & Services > Contract Services > News
Oncternal Therapeutics secures worldwide license to ROR1 antibody from UC San Diego
Oncternal Therapeutics has received an exclusive worldwide license to develop and commercialize antibodies and antibody-related binding agents recognizing Receptor-tyrosine kinase-like orphan receptor 1 (ROR1) from University of California San Diego.
Contract Research & Services > Contract Services > News
EUSA Pharma acquires global rights to Arcoral Tab from Arcoral Pharma
EUSA Pharma has acquired the global rights to a next generation formulation of EUSA's current Caphosol product from Arcoral Pharma.
Contract Research & Services > Contract Services > News
Tobira Therapeutics, Dong-A ST sign license agreements for Evogliptin and Cenicriviroc
Tobira Therapeutics and Dong-A ST Co. have entered into two separate licensing agreements.
Contract Research & Services > Contract Services > News
NMT Pharmaceuticals inks licensing deal with CAO Pharma on anti-cancer drug CZ-48
NMT Pharmaceuticals has signed a licensing agreement with US-based CAO Pharmaceuticals (CAO Pharma) for an exclusive worldwide license right to further develop and market an anti-cancer drug CZ-48 co-developed by CAO Pharma and NMT Pharma.
Contract Research & Services > Contract Services > News
Eisai, PharmStandard sign cooperation agreements in Russia
Japanese research and development pharmaceutical firm Eisai and Russia-based PharmStandard have signed cooperation agreements relating to the localised production of Eisai products in Russia.
Contract Research & Services > Contract Services > News
NantBioScience, NantKwest partner with NCI to further develop recombinant NK cells and monoclonal antibodies
NantBioScience has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), an Institute of the National Institutes of Health (NIH).
Contract Research & Services > Contract Services > News
Portola Pharmaceuticals inks deal with Daiichi Sankyo to develop andexanet alfa with edoxaban
Portola Pharmaceuticals has entered into a clinical collaboration agreement with Daiichi Sankyo to develop andexanet alfa as an antidote for edoxaban, Daiichi Sankyo’s Factor Xa inhibitor, in Japan.
Contract Research & Services > Contract Services > News
Quantum Pharmaceutical signs five-year contract extension with AAH Pharmaceuticals
Quantum Pharmaceutical Limited, the largest business unit in Quantum Pharma's Specials division, has signed a new five-year contract extension with AAH Pharmaceuticals Limited ("AAH").
Contract Research & Services > Contract Services > News
Array BioPharma, Asahi Kasei Pharma collaborate for novel pain and inflammation program
Array BioPharma and Asahi Kasei Pharma announced a strategic collaboration to develop and commercialize select Tropomyosin receptor kinase A (TrkA) inhibitors, including Array-invented ARRY-954, for pain, inflammation and other non-cancer indications.
Contract Research & Services > Contract Services > News
Dr. Reddy's acquires ex-Asia rights to Eisai anti-cancer agent E7777
By PBR Staff Writer
Eisai has signed an agreement to transfer the exclusive global development and commercialization rights, excluding Japan and Asia, to its cancer drug candidate E7777 to Dr. Reddy’s Laboratories.
Contract Research & Services > Contract Services > News
Rich Pharmaceuticals extends CRO deal with Theradex to manage clinical sites in US
Rich Pharmaceuticals has extended its agreement with Theradex Systems to manage its clinical sites in the US.
Contract Research & Services > Contract Services > News
OncBioMune signs MOU for JV with Vitel to develop novel cancer vaccine for Mexico and Latin America
OncBioMune Pharmaceuticals has signed a Memorandum of Understanding (MOU) with Vitel Laboratorios for the purpose of establishing a Joint Venture (JV), to be named OncBioMune Mexico, to develop and commercialize OncBioMune’s portfolio of innovative cancer therapies in Mexico and Latin America.
Contract Research & Services > Contract Services > News
Ligand signs OmniAb platform license agreement with ABBA Therapeutics
Ligand Pharmaceuticals has entered into a worldwide license agreement with ABBA Therapeutics AG, a Swiss biotechnology company developing immuno-oncology therapies.
Contract Research & Services > Contract Services > News
121-135 of 2369 results